Stamatiou Antonia, Herrera-Gómez Ruth Gabriela, Szturz Petr, Bisig Bettina, Romano Edouard, Sykiotis Gerasimos, Gorostidi François, La Rosa Stefano, Kopp Peter, Cristina Valérie
Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne.
Service de pathologie clinique, Département médecine de laboratoire et pathologie, CHUV, et Faculté de biologie et de médecine, Université de Lausanne, 1011 Lausanne.
Rev Med Suisse. 2021 May 19;17(739):962-966.
Anaplastic thyroid cancer (ATC) is among the most aggressive cancers with a median overall survival of 4 months and a disease-specific mortality of close to 100%. As soon as the diagnosis is suspected or established, urgent referral to an experienced multidisciplinary center is imperative. Chemotherapy has limited efficacy. Molecular analyses, together with the availability of novel targeted therapies and immunotherapies, now permit to improve outcomes. In particular, targeted therapy with dabrafenib and trametinib is indicated as first-line therapy for BRAF V600E-mutated ATC.
间变性甲状腺癌（ATC）是侵袭性最强的癌症之一，总生存期的中位数为4个月，疾病特异性死亡率接近100%。一旦怀疑或确诊，必须紧急转诊至经验丰富的多学科中心。化疗疗效有限。分子分析以及新型靶向治疗和免疫治疗的出现，现在有望改善治疗结果。特别是，达拉非尼和曲美替尼的靶向治疗被指定为BRAF V600E突变型ATC的一线治疗方法。
